| pubmed-article:18698027 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18698027 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:18698027 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:18698027 | lifeskim:mentions | umls-concept:C0345967 | lld:lifeskim |
| pubmed-article:18698027 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:18698027 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:18698027 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:18698027 | pubmed:issue | 16 | lld:pubmed |
| pubmed-article:18698027 | pubmed:dateCreated | 2008-8-13 | lld:pubmed |
| pubmed-article:18698027 | pubmed:abstractText | The p21 cyclin-dependent kinase inhibitor was frequently expressed in human malignant pleural mesothelioma (MPM) tissues as well as cell lines. Recent data indicate that p21 keeps tumor cells alive after DNA damage, favoring a survival advantage. In this study, we assessed the possibility of p21 suppression as a therapeutic target for MPM. | lld:pubmed |
| pubmed-article:18698027 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18698027 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18698027 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18698027 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18698027 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18698027 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18698027 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18698027 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18698027 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18698027 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18698027 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:18698027 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:18698027 | pubmed:author | pubmed-author:ProcopioAnton... | lld:pubmed |
| pubmed-article:18698027 | pubmed:author | pubmed-author:CatalanoAlfon... | lld:pubmed |
| pubmed-article:18698027 | pubmed:author | pubmed-author:MorettiSimona... | lld:pubmed |
| pubmed-article:18698027 | pubmed:author | pubmed-author:OrecchiaSaraS | lld:pubmed |
| pubmed-article:18698027 | pubmed:author | pubmed-author:BettaPier-Gia... | lld:pubmed |
| pubmed-article:18698027 | pubmed:author | pubmed-author:LazzariniRaff... | lld:pubmed |
| pubmed-article:18698027 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18698027 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:18698027 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:18698027 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18698027 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18698027 | pubmed:pagination | 5099-107 | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:meshHeading | pubmed-meshheading:18698027... | lld:pubmed |
| pubmed-article:18698027 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18698027 | pubmed:articleTitle | Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma. | lld:pubmed |
| pubmed-article:18698027 | pubmed:affiliation | Department of Molecular Pathology and Innovative Therapies, Marche University, Ancona, Italy. | lld:pubmed |
| pubmed-article:18698027 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18698027 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:1026 | entrezgene:pubmed | pubmed-article:18698027 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:18698027 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18698027 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18698027 | lld:pubmed |
